Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct by Jimenez, Anne-Sophie et al.
METHODOLOGY ARTICLE Open Access
Rapid obtention of stable, bioluminescent tumor
cell lines using a tCD2-luciferase chimeric
construct
Anne-Sophie Jimenez
1, Mélanie Gressette
1, Clément Barjon
1,2, Ming Wei
2, Claire Gourzones
1 and Pierre Busson
1*
Abstract
Background: Bioluminescent tumor cell lines are experimental tools of major importance for cancer investigation,
especially imaging of tumors in xenografted animals. Stable expression of exogenous luciferase in tumor cells
combined to systemic injection of luciferin provides an excellent signal/background ratio for external optical
imaging. Therefore, there is a need to rationalize and speed up the production of luciferase-positive tumor cell
lines representative of multiple tumor phenotypes. For this aim we have designed a fusion gene linking the
luciferase 2 protein to the c-terminus of a truncated form of the rat CD2 protein (tCD2-luc2). To allow simultaneous
assessment of the wild-type luciferase 2 in a context of tCD2 co-expression, we have made a bicistronic construct
for concomitant but separate expression of these two proteins (luc2-IRES-tCD2). Both the mono- and bi-cistronic
constructs were transduced in lymphoid and epithelial cells using lentiviral vectors.
Results: The tCD2-luc2 chimera behaves as a type I membrane protein with surface presentation of CD2 epitopes.
One of these epitopes reacts with the OX34, a widely spread, high affinity monoclonal antibody. Stably transfected
cells are sorted by flow cytometry on the basis of OX34 staining. In vitro and, moreover, in xenografted tumors, the
tCD2-luc2 chimera retains a substantial and stable luciferase activity, although not as high as the wild-type
luciferase expressed from the luc2-IRES-tCD2 construct. Expression of the tCD2-luc2 chimera does not harm cell and
tumor growth.
Conclusion: Lentiviral transduction of the chimeric tCD2-luc2 fusion gene allows selection of cell clones with stable
luciferase expression in less than seven days without antibiotic selection. We believe that it will be helpful to
increase the number of tumor cell lines available for in vivo imaging and assessment of novel therapeutic
modalities. On a longer term, the tCD2-luc2 chimera has the potential to be expressed from multi-cassette vectors
in combination with various inserts of interest.
Backround
Most recent developments in therapeutics against
cancers have underlined the need to adapt treatment
modalities to the molecular and functional characteris-
tics of each tumor. For example, antibodies targeted to
the EGF-receptor provide benefits only for a subset of
colon carcinoma with K-ras mutations [1]. Therefore,
for each tumor type, there is a need for investigations of
novel therapeutic arms on a large number of tumor cell
lines representative of various genotypes and phenotypes.
This requirement applies to in vitro but also in vivo
investigations which are a necessary step for evaluation
of novel therapeutic modalities. To perform these in
vivo explorations, optical imaging is an irreplaceable
tool to assess dissemination of tumor cells in the body
of xenografted mice as well as tumor growth or regres-
sion under treatment [2,3]. Although various types of
reporter genes encoding fluorescent proteins have been
reported, expression of exogenous luciferase combined
to systemic administration of luciferin remains the
strategy of optical imaging providing the best signal/
background ratio [4].
Currently luciferase-positive tumor cell lines are often
produced by transfection of a plasmid containing a
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any medium, provided the original work is properly cited.luciferase expression cassette and a gene encoding anti-
biotic resistance as a selection marker. This approach
has two major drawbacks: it often requires several
weeks of manipulation and the process of antibiotic
selection is a factor of uncontrolled phenotypic changes.
To overcome these problems, we have designed a strat-
egy based on a chimeric protein in which the luciferase
2 is fused to the C-terminus of a truncated form of the
rat CD2 protein. As reported here, this protein behaves
as a type I membrane protein which retains luciferase
activity whereas its CD2 portion is presented at the sur-
face of the plasma membrane. Lentiviral transduction of
the chimeric gene combined to flow cytometry sorting
of CD2-positive live cells allow rapid production and
selection of luciferase-positive cells derived from both
lymphoid and epithelial tumor cells.
Methods
Construction of plasmid inserts containing the luciferase
2 gene
A fusion gene named tCD2-luc2 was assembled in the
pcDNA6.2/V5/GW/D-TOPO (Invitrogen, Cergy Pon-
toise, France). First, a cDNA segment encoding for the
first 232 residues of the rat CD2 (GenBank
ADI96088.1) was PCR-cloned into this plasmid with
addition of an EcoR1 site at the 3’ end of the insert. In
a second step, the full length gene encoding luciferase 2
(Photinus pyralis) was PCR-amplified from pGL4.10
(Promega, Charbonnières-les-Bains, France) with addi-
tion of EcoR1 sites at both ends. Some codons of this
synthetic luciferase 2 have been optimized for more effi-
cient expression in mammalian cells (GenBank
AAV52869.1). In the third step, the luc2 gene was
ligated in the EcoR1 site downstream of the truncated
CD2 gene (T4 ligation). This construct resulted in a
chimeric gene containing the first 232 codons of the rat
CD2, 2 codons corresponding to the EcoR1 site in
frame with the full length luc2 gene, under the control
of the CMV promoter. The pairs of primers designed
for cloning of the CD2 and luc2 segments are presented
in Table 1. A bicistronic construct containing the full
length luciferase 2 and the truncated rat CD2 genes,
was assembled in the pQCXIX plasmid (Takara Bio
Europe/Clontech, Saint-Germain-en-Laye, France). First,
the luciferase 2 gene was PCR-amplified from pGL4.10
(Promega) with addition of Not1 sites at both ends and
an internal Mlu1 site at the 5’ end. The truncated rat
CD2 gene was PCR-amplified with addition of Bcl1 sites
at both ends and an internal Mlu1 site at the 3’ end.
Then, these two genes were inserted into the MCS I (at
the Not1 site) and MCS II (at the Bcl1 site), respec-
tively. They were thus linked by the IRES (Internal
Ribosome Entry System) provided by the pQCXIX plas-
mid. All PCR reactions were done using Finnzymes’
Phusion™ Hot Start High-Fidelity DNA Polymerase
(Ozyme, Saint Quentin, France). Final constructs were
verified by sequencing.
Construction of expression vectors for short-term
transfections
As explained in the previous paragraph, the tCD2-
luc2 fusion gene was assembled directly in the
pcDNA6.2/V5/GW/D-TOPO (Invitrogen). To allow
comparison of the chimeric protein with the wild-
type luciferase 2 in short-term transfections, the wild-
type luc2 gene was PCR-cloned in the same vector at
its EcoR1 site.
Construction of the pro-lentiviral vectors and production
of lentiviral particles
The two inserts of interest - tCD2-luc2 and luc2-IRES-
tCD2 - were cloned in the pLV plasmid (Vectalys SA,
T o u l o u s e ,F r a n c e ) .T h i sp r o - l entiviral plasmid provides
an expression cassette driven by the elongation factor-1
alpha (EF-1 alpha) promoter. This promoter was chosen
for its steady, mild transactivation power which is con-
sistent in vitro and in vivo [5]. The pLV expression cas-
sette also contains at its 3’ end the woodchuck hepatitis
virus post-transcriptional regulatory element (WPRE).
WPRE was shown to stimulate expression of intronless
viral messages not only in cells infected by woodchuck
hepatitis virus, but also in nonviral and heterologous
viral gene delivery systems [6]. Finally the pLV expres-
sion cassette is surrounded by HIV LTRs deleted of the
U3 region [pLV-EF1-tCD2-luc2-WPRE] (Figure 4). The
tCD2-luc2 insert was PCR-cloned at the Mlu1 site of
the pLV vector. The luc2-IRES-tCD2 insert was excised
from the pQCXIX plasmid where it was previously
assembled by an Mlu1 cut and ligated at the Mlu1 site
of pLV. Lentiviral particles were produced by Vectalys
SA. Pro-lentiviral plasmids derived from pLV and con-
taining appropriate inserts were co-transfected in 293T
cells along with two helper plasmids encoding for the
gag and pol HIV genes and the VSV-G Env gene,
respectively.
Cell culture and transfections
The epithelial (293, HeLa and MDA-MB-231) and lym-
phoid cells (Daudi) were grown in DMEM and RPMI
Table 1 Primers used to amplify DNAs coding for a
truncated form of rat CD2 (codons 1-232) and the full-
length luciferase 2
Sequences to amplify Forward primers Reverse primers
rat tCD2 5’CACCATGAGGT
GTAAATTCCTAGGG3’
5’GAATTCCCGTTTTTT
CCTCTTGCAGAT3’
luc 2 5’CACCGAATTCAT
GGAAGATGCCAAA3’
5’GAATTCTTACAC
GGCGATCTTG3’
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Page 2 of 101640 medium, respectively (Gibco-Invitrogen, Cergy
Pontoise, France) with 10% fetal bovine serum (FBS).
For short-term transfections, 293 cells were seeded in
six-well plates at 2.10
5cells/well. On the next day, they
were transfected with increasing concentrations of plas-
mid DNA encoding for the wild-type luciferase 2 (luc2)
or the tCD2-luciferase 2 (tCD2-luc2) chimera (from 0.05
μgt o1μg/well i.e. 25 ng to 500 ng/10
5cells). Transfec-
tion was performed using TurboFect™ in vitro Trans-
fection Reagent (Fermentas, St. Leon-Rot, Germany)
according to the manufacturer’s instructions. Cells were
grown in situ for 48 h prior to cell counts and protein
extraction for luciferase assay and western blot analysis.
Stable transfections in Daudi and Hela cells were made
by lentiviral infection. Target cells were incubated with
recombinant lentiviral particles (multiplicity of infection
2) in the presence of hexadimethrine bromide 4 μg/mL
(Sigma-Aldrich, St Quentin Fallavier, France) to enhance
transfection efficiency [7]. Forty-eight hours later, trans-
duced cells were extensively washed and subjected to
flow cytometry sorting on the basis of OX34 staining.
Luciferase assay
Luciferase activity in cell extracts was assessed using the
Promega Luciferase Assay System according to the
manufacturer instructions (Promega). Washed cells
were lysed using the lysis reagent provided in the kit.
The Plate-Reading luminometer’s injectors added 50 μL
of the kit Luciferase Assay Reagent providing the
D-Luciferin substrate into 96-well plate containing
10 μL of cell lysate per well. Photon emission was mea-
sured for a period of 10 seconds with a delay time of
2 seconds after injection of the substrate.
Western blot analysis
Proteins from cultured cells were extracted by lysis in
RIPA buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA,
0.5% sodium deoxycholic acid, 0.5% NP-40, 0.1% SDS)
supplemented with a protease inhibitor cocktail (Com-
plete, Roche Applied Science, Neuilly-sur-Seine, France).
Once sonicated on ice, protein extracts were clarified by
centrifugation for 15 minutes at 16 000g at 4°C and sub-
jected to SDS-PAGE. Proteins were then transferred to
polyvinylidene difluoride membranes (Immobilon, Milli-
pore, Billerica, CA) by electroblotting at 4°C for 90 min-
utes at 90 V. The antibodies used for Western blot
analysis were the OX34 mouse monoclonal antibody
directed against rat CD2 (hybridoma kindly provided by
Pr Martin Rowe, Birmingham) [8] and a purified poly-
clonal antibody raised in goats against recombinant fire-
fly luciferase (Promega) [9]. Blots were incubated with a
secondary peroxidase-conjugated antibody and chemilu-
minescent detection was done using the Immobilon
Western Chemiluminescent HRP Substrate (Millipore).
When required, primary antibodies were removed from
the blotted membrane using the ReBlot Plus Strong
Antibody Stripping Solution (Chemicon, Millipore) for 5
to 20 minutes at room temperature.
Flow cytometry analysis and sorting of cells transduced
by the recombinant constructs
Transfected cells were treated with 5% FBS in PBS for 30
minutes to block non-specific staining. They were then
incubated with the OX34 monoclonal antibody (IgG2a),
diluted 1:200 in PBS with 3% FBS, and with secondary
polyclonal goat anti-mouse immunoglobulins labelled
with phycoerythrin (Dako Denmark A/S, Glostrup,
Denmark) diluted at 20 μg/ml in PBS with 3% FBS.
For cell sorting, about 5 millions cells were sorted
using the MoFlo
® Flow Cytometer (Beckman-Coulter,
Villepinte, France) with a gate of at least two logs of
fluorescence intensity above the backround (non trans-
fected control cells). Sorted cells (from 10 to 40%) were
collected in 96 well-plates at a density in the range of
5000 to 50000 cells per well.
Assessment of in vitro cell growth by MTT reduction
assay
Daudi and HeLa cells were seeded in 96-well plates at a
density of 25 000 and 5 000 cells, respectively, with
100 μl culture medium per well. An MTT (Thiazolyl
Blue Tetrazolium Blue) reduction assay was used to
assess the amount of viable cells. MTT powder (Sigma)
was solubilized in PBS to make a stock solution at
250 mg/ml. 25 μl of this stock solution were added to
each well subjected to this assay. After 4 h of incuba-
tion, 100 μl of solubilisation buffer (0.7 M SDS; 4.5 M
dimethyl-formamide; 0.02N acetic acid; 1N HCl; pH 7.4)
were added to each well to solubilize the formazan salt
resulting from MTT reduction. The amount of product
was evaluated by absorption at 550 nm on a spectro-
photometer. Assessment of viable cells was performed
just after seeding and for the next 3 days.
Obtention of xenografted tumors
Eight-week-old female nude mice were anesthetized
with 3% isoflurane. Prior to subcutaneous injection,
6.10
6 viable control or stably transfected Daudi cells
were suspended in a mix of RPMI medium (100 μl) and
BD Matrigel™ (100 μl) (growth factor reduced) (BD
Biosciences, Le Pont de Calix, France).
Bioluminescent imaging (BLI)
For in vivo imaging, mice were treated by intraperitoneal
injection (150 mg/kg in PBS) of the D-luciferin substrate
(Promega). The anesthetiz e dm i c ew e r ep l a c e do n t o
warmed stage inside the light-tight IVIS 50 box. In this
study, mice were imaged fifteen minutes after D-luciferin
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the oxidation of the substrate. The IVIS 50 camera sys-
tem was used to visualize tumors, and photon measure-
ment was defined around the tumor area and quantified
using Living Image software (Xenogen for Caliper Life
Science SA, Villepinte, France).
Results
Short-term expression of the tCD2-luciferase 2 chimera in
293 cells
A chimeric gene combining the first 232 codons of the
rat CD2 (tCD2) to the full length gene encoding for
luciferase 2 (Photinus pyralis) was inserted in a eukar-
yote expression plasmid under the control of the CMV
promoter. In order to check that the chimeric gene was
effectively translated in a protein, it was expressed in
293 cells by short-term transfection. Simultaneously, the
wild-type luciferase 2 gene was transfected in the same
cells using the same promoter in the same plasmid vec-
tor. A substantial luciferase activity was detected in cells
transfected with the tCD2-luciferase 2 (tCD2-luc2)c o n -
struct as well as the wild-type luciferase 2 (luc2)g e n e
(Figure 1). In both cases, a substantial level of luciferase
activity was obtained for concentrations of plasmids
equal or lower than 250 ng/10
5 cells. Simultaneously the
tCD2-luc2 and luc2 proteins were detected by western
blot analysis in protein extracts of transfected cells using
similar amounts of plasmids (about 250 ng/10
5 cells)
(Figure 2). The tCD2-luc2 chimera was detected with
even lower plasmid concentrations - in the range of 50
ng/10
5 cells - when staining its CD2 portion on the
surface of live cells using the OX34 antibody and flow
cytometry analysis (Figure 3).
Long-term in vitro expression of the tCD2-luciferase 2
chimera in the context of lymphoid and epithelial cells
Our next goal was to assess the expression level of
tCD2-luc2 in stably transfected cells and its impact on
cell viability. For this aim, the tCD2-luc2 fusion gene
was inserted in a lentiviral vector under the control of
the EF-1 alpha promoter (Figure 4, monocistronic con-
struct). Simultaneously, another construct was built in
order to compare the chimeric protein to the wild-type
luciferase in a context of co-expression with the trun-
cated rat CD2 but without fusion of these two species.
For this aim, the wild-type luciferase gene driven by the
EF1-alpha promoter was combined to the truncated
C D 2g e n ed r i v e nb ya nI n t e r n a lR i b o s o m eE n t r yS i t e
(IRES). This bicistronic construct called luc2-IRES-tCD2
was inserted in the same lentiviral vector as the one
used for tCD2-luc2 (Figure 4, bicistronic construct).
Both types of lentiviral particles were used to transduce
lymphoid (Daudi) and epithelial (Hela) cells in order to
make stable transfectants. In each of these four experi-
mental conditions, more than 80% cells were transfected
as shown by staining of the CD2 protein at the surface
of live cells and flow cytometry analysis using the OX34
antibody (data not shown). CD2-positive cells were sub-
sequently sorted by flow cytometry to get rid of the
minority of untransfected cells. After expansion of
sorted cells for at least two weeks, luciferase activity was
repeatedly investigated in the extracts of Daudi and
Hela cells (Figure 5). A significant activity was consis-
tently detected in the tCD2-luc2 transfectants although
not as intense as for luc2-IRES-tCD2 transfectants.
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Figure 1 Luciferase activity in 293 cells following short-term
transfection of the wild-type luciferase 2 and tCD2-luciferase 2
genes. Recipient epithelial cells (293) were seeded at 2.10
5/well in
6-well plates and transfected using the Turbofect reagent
(Fermentas) with increasing concentrations of plasmid DNA
encoding either for the wild-type luc2 or the tCD2-luc2 chimera.
They were grown in situ for 48 h prior to protein extraction and
luciferase assay. For each condition, luciferase activity was
normalized according to cell counts made on a fraction of the cells
collected for the luciferase assay. This experiment was repeated six
times (n = 6). Error bars represent SD of 6 experiments. Luciferase
activities are significantly different for the two genes when using
500 ng of transfected plasmid (Mann&Whitney test, p < 0.05).
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Figure 2 Western blot analysis of luciferase 2 (luc2) and tCD2-
luc 2 proteins in short-term transfected 293 cells. The 293 cells
were seeded and transfected as explained in the legend of Figure 1.
They were grown in situ for 48 h prior to protein extraction and
western blot analysis. The wild-type luciferase 2 and the tCD2-luc2
chimera are pointed out by an arrowhead and a star, respectively.
An apparent cleaved fragment of the tCD2-luc2 protein with a size
identical to the wild-type luciferase 2 is pointed out by a dash. The
western blot membranes were restained with an anti-actin (Sigma)
for loading control.
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Page 4 of 10Similar levels of luciferase activity were recorded in
another epithelial cell line - MDA-MB-231 - stably
transfected with the tCD2-luc2 construct (data not
shown). As shown in Figure 6, the tCD2-luc2 and luc2
proteins detected by western blotting, were in the same
range of concentrations in both types of stable transfec-
tants, suggesting that the above-mentioned difference in
luciferase activity was related to sub-optimal activity of
the chimeric protein rather than to its weak production
or rapid degradation. Like for short-term transfected
293 cells, a minor cleaved fragment of the tCD2-luc2
protein with a size identical to the wild-type luciferase 2
was detected in stably transfected Hela cells (Figures 2
and 6). However, the intact fusion protein was clearly
predominant with anti-luciferase as well as anti-CD2
staining. Finally surface CD2 staining and flow cytome-
try analysis was performed after at least 4 weeks of con-
tinuous growth (Figure 7). Massive and homogeneous
surface expression of CD2 was recorded for transfected
Daudi and Hela cells. The mean fluorescence was
slightly higher for the tCD2-luc2 compared to the luc2-
IRES-tCD2 construct in Daudi cells whereas it was the
opposite for Hela cells.
Absence of adverse effects of the tCD2-luciferase 2
chimera on cell growth in vitro
Cell viability and growth assays were performed simulta-
neously on wild-type Daudi cells and their counterparts
Transfected plasmid M1 M2
a. none 99.71 % 0.29 %
b. luc2 (500ng/105 cells) 99.55 % 0.45 %
c. tCD2-luc2 (25ng/105 cells) 94.04 % 5.96 %
d. tCD2-luc2 (250ng/105 cells) 25.75 % 74.25 %
e. tCD2-luc2 (500ng/105 cells) 1.50 % 98.50 %
Isotype control + GAM-PE
OX34 + GAM-PE
a. c. b. d. e.
CD2-fluorescence CD2-fluorescence CD2-fluorescence CD2-fluorescence CD2-fluorescence
Figure 3 Cell surface expression of the recombinant CD2 following short-term transfection of the tCD2-luc 2 gene in 293 cells.T h e
293 cells were stained with the OX34 MAb reacting with a cell surface epitope of the rat CD2 protein. The M1 and M2 cell populations are defined
according to the threshold of background fluorescence. For assessment of the background fluorescence, cells were first incubated with the mouse
isotype control IgG2a (instead of the OX34) and then with the secondary antibody conjugated to phycoerythrin (goat anti-mouse-PE or GAM-PE).
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Figure 4 Structure of monocistronic and bicistronic constructs
inserted in lentiviral vectors for combined expression of the
luciferase 2 and truncated rat CD2 proteins. Lentiviral vectors
were designed for expression of the luciferase 2 protein combined
with a truncated form of the rat CD2 (tCD2) protein either as a
fusion protein (monocistronic insert) or as two distinct proteins
(bicistronic insert). Both types of constructs are inserted at an EcoR1
site in the pro-lentiviral plasmid under the control of the EF-1 alpha
promoter and flanked by the WPRE sequence. Recombinant
lentiviral particles were produced by tri-transfection in 293T cells as
explained in the Materials and Methods section.A) The tCD2-luc2
insert contains the first 232 codons of the rat CD2 gene fused to 2
codons GAA (glutamic acid) and GTC (valine) added for cloning
purpose (EcoR1 site) in frame with the full length luciferase 2 gene
starting at codon 236.B) The bicistronic insert - luc2-IRES-tCD2 -
contains the full length luciferase 2 gene linked by an IRES (Internal
Ribosome Entry System sequence) to the truncated rat CD2 gene.
This IRES (573 base pairs) was derived from the pQCXIX plasmid
(Clontech).
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Page 5 of 10stably transfected with the tCD2-luc2 and luc2-IRES-
tCD2 constructs. The amount of live cells was assessed
in 96-well plates after one, two or three days of culture
by an MTT-reduction assay. As shown in Figure 8, cell
growth was identical in wild-type Daudi cells and both
types of transfectants therefore providing no evidence of
a toxic effect of the exogenous proteins, including the
tCD2-luc2 chimera. The same observations were made
for the transfected Hela cells using the same experimen-
tal methods (Figure 8).
In vivo assessment of the tCD2-luciferase 2 chimera in
xenografted tumors derived from Daudi cells
In order to prove that the cells expressing the tCD2-
luc2 protein had appropriate luciferase activity for
in vivo imaging, xenografted tumors were generated in
nude mice by subcutaneous injections of wild-type,
tCD2-luc2 and luc2-IRES-tCD2 transfected Daudi cells
(three mice for each condition). After subcutaneous
injection of 6.10
6 cells, tumors were visible as early as
two weeks post-injection. Using an optical imaging sys-
tem, substantial photon emission was recorded at days
20 and 28 post-injection for tumors carrying the tCD2-
luc2 and the luc2-IRES-tCD2 constructs (Figure 9).
Mice were sacrificed at day 28 just after assessment of
bioluminescence, allowing immediate weight measure-
ment for each tumor and its use as an index of tumor
growth. There was a trend toward higher weights for
tumors expressing the tCD2-luc2 chimera by compari-
son with the wild-type Daudi cells and cells expressing
wild-type luciferase 2 from the luc2-IRES-tCD2 con-
struct. This is a good indication that the tCD2-luc2
chimera is devoid of cell toxicity in vivo as well as in
vitro. As shown on the bottom graph of Figure 9,
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Figure 5 Luciferase activity in stable lymphoid and epithelial
transfectants carrying recombinant luciferase constructs.
Luciferase activity was assessed in protein extracts from Daudi and
HeLa cells with stable expression of monocistronic (tCD2-luc2)o r
bicistronic (luc2-IRES-tCD2) luciferase constructs. The substrate was
D-luciferin (Promega luciferase assay system, Promega). Light
measurements were done on a Microlumat LB96P luminometer
(Berthold, Thoiry, France). This experiment was repeated thrice; error
bars represent SD of three experiments (n = 3). Error bars are not
apparent above rectangles corresponding to Daudi luc2-IRES-tCD2
and Hela tCD2-luc2 because experimental data for these conditions
were very consistent (very small error bars are not apparent for this
size of the graph using the Microsoft Excel software).
Anti-actin
(1 sec expo)
55
40
Anti-CD2 
(1 sec expo)
130
90
72
55
40
Anti-luciferase
(10 sec expo)
Daudi HeLa
Control
tCD2-luc2
luc2-IRES-tCD2
Anti-actin
(1sec expo)
55
40
Control
tCD2-luc2
luc2-IRES-tCD2
130
90
72
55
Figure 6 Western blot analysis of recombinant luciferase and
rat CD2 proteins in stable lymphoid and epithelial
transfectants. Protein extracts were prepared from stably
transfected Daudi and Hela cells as well as from the corresponding
control cells. After gel separation and membrane transfer, these
extracts were analysed using antibodies directed to the luciferase
protein or the rat CD2.The tCD2-luc2 chimera, the wild-type
luciferase 2 and the truncated rat CD2 are pointed out by a star, an
arrowhead and an arch, respectively. The western blot membranes
were restained with an anti-actin for loading control. A minor
cleaved fragment of the tCD2-luc2 protein with a size identical to
the wild-type luciferase 2 is detected at a low level in the extract of
Hela cells transfected with the tCD2-luc2 fusion gene.
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Figure 7 Flow cytometry detection of cell surface recombinant
CD2 in stable lymphoid and epithelial transfectants. Stably
transfected cells of lymphoid (Daudi) or epithelial (Hela) origin were
stained with the OX34 MAb reacting with a cell surface epitope of
the rat CD2 protein. The threshold of background fluorescence was
defined according to cells incubated with the mouse isotype
control IgG2a instead of the OX34, as explained for Figure 3.
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Page 6 of 10although the average photon emission per mg of tumor
tissue in tumors expressing the chimera is not as high
as for the wild-type luciferase 2, it is well above the
background emission recorded from control tumors (4
log difference).
Discussion
The aim of this study was to obtain a system allowing
rapid conversion of human tumorigenic cell lines into
cell lines with stable luciferase expression, without anti-
biotic selection. This goal has been achieved by lentiviral
transfection of two types of gene constructs: one is a
monocistronic insert containing the chimeric tCD2-luc2
gene; the other one is a bicistronic insert resulting in
concomitant expression of the wild-type luciferase 2 and
the truncated rat CD2 as two distinct protein species.
One advantage of the second strategy is to provide
higher luciferase activity in vitro and in vivo.T h i si s
probably due to a sub-optimal enzymatic function of the
chimeric luciferase. Insect luciferases are members of
the acyl-adenylate/thioester-forming superfamily of
enzymes [10]. They are evolutionary related to the fatty
acyl-CoA synthetases which in physiological conditions
are located in the outer mitochondrial membranes. The
initial reaction catalyzed by firefly luciferases on their
luciferin substrate is the formation of luciferase-bound
luciferyl-adenylate in the presence of Mg++ and ATP.
There are two options for the second step. Either oxyge-
nation of luciferin resulting at the final stage in photon
emission, release of AMP and CO2. Or formation under
anaerobic conditions of a thio-ester bound between luci-
ferin and co-enzyme A (L-CoA). These second step
reactions are mutually exclusive. One can speculate that
fusion of luciferase 2 to tCD2 changes its sub-cellular
distribution and/or impairs its folding pattern [11]. As a
consequence, formation of L-CoA might be enhanced at
the expenses of luciferin oxygenation or both reactions
might be inhibited. This issue will require further inves-
tigations to determine the subcelullar distribution of
tCD2-luc2 chimera in the internal membrane network
and if possible its secondary and tertiary structures. It
remains that the bicistronic insert luc2-IRES-tCD2
might be a better choice when a very high sensitivity is
required, for example for detection of very small lung
metastases. However, on the long term, we favor the
fusion protein strategy because two functions are
achieved in a unique cistron: presentation of a mem-
brane epitope for cell sorting and bioluminescence. In a
multi-cassette expression vector, this compaction of two
functions in a single protein will leave room for other
inserts coding for proteins or transcripts of interest.
Previous studies have shown that N-terminal or
C-terminal luciferase fusion proteins can be produced
in vivo retaining luciferase enzymatic activity [12,13].
However both types of fusion proteins were GFP-luciferase
proteins. To our knowledge, we are the first to report a
chimeric protein combining the luciferase moiety with a
type I membrane protein. We demonstrated that the
tCD2-luc2 protein retains luciferase activity whereas its
CD2 portion is presented at the surface of the plasma
membrane. This applies to various cell types both in short
and long term transfectants. In addition, our data suggest
that the tCD2-luc2 protein do not induce significant cyto-
toxic effects in vitro as well as in vivo.
One important aspect of our experimental system is
the use of recombinant VSV-G pseudotyped lentiviruses
which can infect almost any cell type, both dividing and
non-dividing. Lentiviral infection results in reverse tran-
scription of the viral RNA genome and synthesis of a
double strand proviral DNA which is inserted in the cel-
lular genome by the viral integrase. Last generation self-
inactivating lentiviruses exclude genes for viral genome
replication and virion production, not only providing
safety for use, but also stabilizing the integrated gene.
These features enable simultaneous stable gene delivery
in a large fraction of recipient cells thus allowing flow
cytometry or bead capture selection instead of drug
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Figure 8 Impact of the expression of luciferase constructs on
lymphoid and epithelial cell growth in vitro. The viability and
growth of stably transfected cells of lymphoid (Daudi) or epithelial
(Hela) origin were tested in three day assays in 96-well plates
(25000 and 5000 cells seeded per well at day 0 for Daudi and Hela
cells, respectively). The amount of live cells per well was measured
by an MTT reduction assay. Both experiments were repeated six
times; error bars represent SD of 3 experiments (n=3).
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Page 7 of 10selection [14]. Another important characteristic of our
system is the choice of a cellular house-keeping gene
promoter with mild activity, the promoter of the EF-1a
gene encoding for the human elongation factor-1a.
According to previous studies such promoters are better
suited to ensure sustainable and consistent activity of
the transfected genes [12,15].
One alternative to bioluminescent imaging (BLI) is
optical imaging based on a fluorescent protein expressed
by tumor cells, for example GFP (l emission = 510 nm) or
red fluorescent proteins such as tdTomato (l emission =
581 nm) or mCherry (l emission = 610 nm) [16]. One
major advantage of fluorescence-based imaging is that it
does not require substrate injection but it has a major
limitation due to high auto-fluorescence of animal tis-
sues resulting in a poor signal to noise ratio. In contrast
when adequate substrate concentration is attained biolu-
minescence provides sensitive detection with unsur-
passed signal to noise ratios due to a lack of
autobioluminescence [4]. However direct flow cytometry
sorting of luciferase-transfected cells is not possible in
routine conditions. One way to overcome this problem
is to produce tumor cells combining expression of luci-
ferase with expression of a fluorescent protein like GFP
or tdTomato using fusion genes or bicistronic con-
structs [12,13,17] However our system of combined
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Figure 9 In vivo imaging of bioluminescent tumors containing two types of luciferase expression constructs. Stably transfected Daudi
cells (6.10
6 cells) were injected subcutaneously into the flank of nude mice forming visible tumors on average two weeks later. The resulting
tumors were imaged after intra-peritoneal injection of the D-luciferin reagent using an IVIS 50 (Xenogen). Three series of three mice were
imaged 20 and 28 days following injection of wild-type Daudi cells (used as controls, upper line of the left panel), Daudi cells transfected with
the monocistronic luciferase construct (medium line) or the bicistronic construct (bottom line). At day 28, tumors were collected and weighted
just after the imaging procedure. In the right panel, are plotted tumor weights (upper graph), total photon flux (medium graph) and the ratios
of photon flux to tumor weights (bottom graph). The stars indicate a statistical difference from controls (Kruskal-Wallis one-way analysis, p <
0.06). Although in this experiment, injection of Daudi cells containing the tCD2-luc2 construct resulted in bigger tumors than the wild-type Daudi
cells, this effect was not observed in another experiment (data not shown). These data as well as the results presented in this figure and in
Figure 8 confirm that the tCD2-luc2 protein does not prevent cell growth in vivo as well as in vitro.
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Page 8 of 10expression of luciferase and truncated CD2 could appear
as an interesting alternative tool in two circumstances.
First, some cell types do not tolerate GFP expression
even at low concentrations. Its toxic effects have been
described in non-malignant and malignant cells as well
[18,19]. These toxic effects are, at least in part, related
to inhibition of poly-ubiquitination [19]. They are prob-
ably underreported; in our own experience we have
observed that some human nasopharyngeal carcinoma
cell lines do not tolerate even low concentrations of
GFP (Vicat et al., 2003 and unpublished observations)
[20]. Since many fluorescent proteins were derived from
GFP, they might not be tolerated in some cellular back-
grounds as well. In such contexts, our tCD2-luciferase
tool might provide a useful alternative. The same applies
to in vivo experiments involving tumor targeting agents
which are fluorescently labeled in order to assess their
effective tumor homing, for example fluorescent nano-
particles, antibodies or antisens RNAs [21]. In these
situations, it might be better to deal with non-fluorescent
luciferase-positive tumor cells instead of using multiple
chromophores.
Conclusions
We here report the construction and characterization of
a chimeric protein linking the N-terminus of the full-
length luciferase protein to a truncated form of the rat
CD2 protein. We demonstrate that the chimeric protein
achieves plasma membrane insertion while retaining
luciferase activity. Long-term, stable expression of this
chimera is readily obtained in various human tumor cell
lines by lentiviral transduction combined to flow cyto-
metry sorting using an antibody directed to the rat CD2.
Drug selection of tumor cells is not required for use of
this experimental system. It is expected to be useful for
experiments where stable GFP, labelling of tumor cells
h a st ob ea v o i d e d .T h et C D 2 - l u c 2p r o t e i na l s oo p e n s
interesting perspectives for use in multi-cassette vectors,
for example vectors containing one cassette coding for a
shRNA combined to a cassette coding for a tracer
protein.
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